Loading
The first thing a lymphoma report says is which kind of lymphocyte the cancer came from. B cells make antibodies and carry a surface protein called CD20; T and NK cells kill infected cells directly and carry no CD20. That single difference is why B-cell lymphomas have had thirty years of new antibody treatments and T-cell lymphomas have not.
Lymphocytes come in three lineages and a lymphoma inherits the one it arose from. B cells mature in the bone marrow and in the germinal centres of lymph nodes, and make antibodies. T cells mature in the thymus and either help other immune cells or kill infected ones. Natural killer cells kill without needing to recognise a specific antigen, and share many surface proteins with cytotoxic T cells, which is why the classifications treat T-cell and NK-cell lymphomas as one group.
The proportions are lopsided. In the UK Haematological Malignancy Research Network series of 5,796 lymphomas, 94.7 per cent were B-cell and 5.3 per cent T-cell. The outcomes are lopsided in the same direction: five-year relative survival was 68.8 per cent for the B-cell group and 45.4 per cent for the T-cell group.
The reason is mostly pharmacological rather than biological. B cells carry CD20, a protein with no essential function that the body can do without, so an antibody against it can be given safely and kills the lymphoma along with the normal B cells. Rituximab was licensed in 1997 and every later B-cell treatment, from antibody-drug conjugates to CAR-T to bispecific antibodies, built on the same idea of a surface address. T cells have no equivalent: the obvious targets are proteins the healthy T cells need, so removing them removes the immune system, and a CAR-T cell aimed at a T-cell protein attacks the other CAR-T cells, a problem called fratricide that the engineering is only now starting to solve.
On a report, the lineage is read from immunohistochemistry: CD20, CD79a and PAX5 for B cells, CD3, CD2, CD5 and CD7 for T cells, CD56 and cytoplasmic CD3 for NK cells. A clonal rearrangement of the immunoglobulin or T-cell receptor genes confirms that the population is a single clone rather than a reaction.
Backbone ribbon from PDB 6VJA. RCSB PDB 6VJA. The ribbon widens where the chain is folded into a regular pattern and narrows where it is a loose loop.
Showing the molecule this term concerns: Rituximab.
Shares ALK-negative anaplastic large cell lymphoma, ALK-positive anaplastic large cell lymphoma, Adult T-cell leukaemia/lymphoma, Extranodal NK/T-cell lymphoma and the tags heme, lymphoma.
Shares T-cell/histiocyte-rich large B-cell lymphoma, Lymphoma (tissue type), The two lymphoma classifications of 2022 (WHO-HAEM5 and ICC), Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome) and the tags heme, lymphoma.
Shares Adult T-cell leukaemia/lymphoma, Lymphoma (tissue type), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Non-Hodgkin lymphoma (all types) and the tags heme, lymphoma.
Shares Breast implant-associated anaplastic large cell lymphoma, Plasmablastic lymphoma, Lymphoma (tissue type), Extranodal NK/T-cell lymphoma and the tags heme, lymphoma.
Shares T-cell/histiocyte-rich large B-cell lymphoma, EBV-positive diffuse large B-cell lymphoma, The two lymphoma classifications of 2022 (WHO-HAEM5 and ICC), CD20 and the tags heme, lymphoma.
Shares Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tags heme, lymphoma.
Shares Non-Hodgkin lymphoma (all types) and the tags heme, lymphoma.
Shares ALK-negative anaplastic large cell lymphoma, ALK-positive anaplastic large cell lymphoma, The two lymphoma classifications of 2022 (WHO-HAEM5 and ICC), Brentuximab vedotin and the tags heme, lymphoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/